2026's Game-Changer: How OSCA from Gangstem Biotech is Revolutionizing Osteoarthritis Care
AI 요약 정보
- Kangstem Biotech tests OSCA for moderate knee osteoarthritis
- Phase 2a: both doses show significant pain and function gains
- MRI MOCART scores improve; medium dose reaches significance